This was the stock's third consecutive day of losses.

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

following Regeneron's announcement of a new dividend. Bernstein SocGen Group revised its price target to $1,000, retaining an Outperform rating, after Dupixent's fourth-quarter sales fell short of ...

Investors seeking value (deep pullbacks) and growth (upside potential) may want to take a closer look at Regeneron fundamentally and technically. Dupixent Generated $14 Billion in 2024 ...

Regeneron Pharmaceuticals has built its success on a foundation of innovative drug development, with key products including Eylea for eye diseases and Dupixent for various inflammatory conditions.

Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with ...

aligning Regeneron with other large-cap biotech firms. Bernstein cut its target to $1,000, keeping an Outperform rating, and highlighted an anticipated earnings per share shortfall due to Dupixent's ...